A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
Type 2 Diabetes Mellitus

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
The prospective participant must meet, at least, all of the criteria below (among others determined by the study staff) to be eligible for study participation.
The participant:
- Has type 2 diabetes mellitus and is between 18 and 70 years of age; for Japan, 20 to 70 years of age;
- Has a body mass index (BMI) > 20 kg/m^2 and < 43 kg/m^2; for Japan: BMI >18 kg/m^2 and <43 kg/m^2;
- Is currently not on an antihyperglycemic agent (AHA) medication (off for ≥ 14 weeks) or is on oral AHA therapy but has inadequate glycemic control;
- Is a male, or a female who is highly unlikely to conceive.
Exclusion Criteria:
If the prospective participant meets any of the criteria below (among others determined by the study staff) they will NOT be eligible for study participation.
The participant:
- Has a history of type 1 diabetes mellitus or a history of ketoacidosis;
- Is on a weight loss program or has started a weight loss medication within the prior 8 weeks;
- Has required insulin therapy within 14 weeks prior to signing informed consent;
- Has a medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic active hepatitis B or C, cirrhosis, or symptomatic gallbladder disease;
- Has congestive heart failure or has new or worsening signs or symptoms of coronary heart disease;
- Had any of the following disorders within the past 3 months: acute coronary syndrome, coronary artery intervention, stroke or transient ischemic neurological disorder;
- Has a history of malignancy or clinically important hematological disorder
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Experimental
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
Experimental
Active Comparator
Omarigliptin 0.25 mg (Base)
Omarigliptin 1 mg (Base)
Omarigliptin 3 mg (Base)
Omarigliptin 10 mg (Base)
Omarigliptin 25 mg (Base)
Placebo (Base)
Pooled omarigliptin (Extension)
Placebo/Metformin
Omarigliptin 0.25 mg administered once weekly for 12 weeks (Base)
Omarigliptin 1 mg administered once weekly for 12 weeks (Base)
Omarigliptin 3 mg administered once weekly for 12 weeks (Base)
Omarigliptin 10 mg administered once weekly for 12 weeks (Base)
Omarigliptin 25 mg administered once weekly for 12 weeks (Base)
Matching placebo to omarigliptin administered once weekly for 12 weeks (Base)
Participants who received omarigliptin during the base study, received omarigliptin 25 mg once weekly and placebo to metformin once daily for 66 weeks (Extension).
Participants who received matching placebo to omarigliptin during the base period, received pioglitazone administered once daily and matching placebo to omarigliptin once weekly for 66 weeks (extension period). Note: A protocol amendment removed pioglitazone during the extension period. Participants discontinued pioglitazone and switched to blinded metformin. Participants who were previously rescued with open-label metformin during the base period continued in the extension period on open-label metformin.